Study designs Clause Samples
Study designs. After evaluators choose a framework, they are ready to select an appropriate study design. There are three kinds of designs: the simple before-after evaluation, the controlled before-after evaluation, and the randomized controlled trial. The simple before-after design is the most commonly used non-experimental design for information system evaluation. In this design, the evaluation team will compare the current system performance with its previous performance. Of course, an appropriate amount of time should be left to allow the new system to be fully functional. Moreover, measuring indicators repeatedly at different time points may also help to show the reliability of those effects (Shojania KG et al. 2005).
Study designs. A double-blind, stratified and randomised evaluation of AZD5363 when combined with weekly paclitaxel vs. weekly paclitaxel plus placebo. Approximately 100 female patients, with ER+ve advanced or metastatic breast cancer will be enrolled in this phase, of which approximately 50 must have a tumour detectable as carrying a PIK3CA mutation. The dose and schedule of AZD5363 will be selected as an outcome from the safety run-in, Part A. All enrolled patients will be stratified to either the PIK3CA mutation ‘detected’ or ‘not detected’ group by the outcome of two tests (tissue and blood (ctDNA)). If a patient is detected as having the PIK3CA mutation in both or either of the two tests, they will be assigned to the mutation detected strata. If the mutation is not detected in both of the two tests, (or should one test be not detected and the other is either unknown or not completed for any reason) the patient will be assigned to the not detected strata. This will be referred to as the protocol definition of PIK3CA mutational status. Patients within each stratum will be randomised to 28-day cycles comprising either of: • Paclitaxel 90 mg/m2 IV once weekly plus AZD5363 capsules taken orally, twice daily. • Paclitaxel 90 mg/m2 IV once weekly plus AZD5363-matching placebo capsules taken orally, twice daily. The overall study plan for PART B is shown in Figure 1.